Canada markets closed
  • S&P/TSX

    20,571.30
    -50.09 (-0.24%)
     
  • S&P 500

    4,410.13
    +12.19 (+0.28%)
     
  • DOW

    34,364.50
    +99.13 (+0.29%)
     
  • CAD/USD

    0.7913
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    83.64
    +0.33 (+0.40%)
     
  • BTC-CAD

    45,657.22
    -53.93 (-0.12%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • GOLD FUTURES

    1,842.60
    +0.90 (+0.05%)
     
  • RUSSELL 2000

    2,033.51
    +45.59 (+2.29%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • NASDAQ futures

    14,318.50
    -182.50 (-1.26%)
     
  • VOLATILITY

    29.90
    +1.05 (+3.64%)
     
  • FTSE

    7,297.15
    -196.98 (-2.63%)
     
  • NIKKEI 225

    27,113.13
    -475.24 (-1.72%)
     
  • CAD/EUR

    0.6987
    +0.0004 (+0.06%)
     

DNA; SRNG Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Lead Plaintiff Deadline: January 18, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • DNA

NEW YORK, November 29, 2021--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. ("Ginkgo" or the "Company") (NYSE: DNA; SRNG) (f/k/a Soaring Eagle Acquisition Corp.) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Owlet between May 11, 2021, and October 5, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/dna.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) as a result, most, if not all, of the Company’s revenue came from related parties the Company created, funded, or controlled through its ownership and board seats; (3) the Company was misclassifying and underreporting related party revenue in order to conceal the Company’s near total-dependence on related parties; (4) many of the Company’s new R&D partners are undisclosed related parties and/or façades; (5) as a result, the Company’s valuation was significantly less than Defendants disclosed to investors; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/dna or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ginkgo you have until January 18, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005011/en/

Contacts

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting